Explore Our Library of Biomanufacturing Resources & Technical Data

Application Notes

rHSA Reconstitution Video Protocol

Exbumin – Reconstitution Application Note

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Blog

Evolving Challenges in Closed-System Biomanufacturing

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?

Data Sheets

Exbumin – Data Sheet

News

InVitria Launches Optibumin 25 rHSA

Posters

Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration

Advancing Vaccine Excellence

Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

Product Brochures

InVitria Product Catalog – 2025

SDS

Exbumin – Safety Data Sheet

Use Guidelines

Exbumin – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation

Emergence of Blood-Free Recombinant Human Albumin

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin